위암 및 췌장암 환자의 혈청에서 CA 242, CA 72-4, MG 7 Ag, CA 19-9 및 CEA 검사의 진단적 의의

Abstract

Gastric cancer is one of the most prevalent malignant tumor among Korean population. Serum tumor markers, including CA 72-4, CA 19-9 and carcinoembryronic antigen (CEA) have been widely used for diagnosis of gastric cancer and Pancreatic cancer. Since 1986, a series of monoclonal antibodies were studied in gastric cancer, designated as MG 7, using activated gastric cancer cells. Recently the clinical concerns are increased by reports that the level of CA 242 is high in serum of cancer patients. This study was perfonned for the purpose of investigating clinical value for CA 242, and MG 7 Ag for the diagnostic marker of gastric cancer and Pancreatic cancer. CA 72-4, CA 19-9 and CEA were also determined. For this study, 42(4이 13) and 50 cases from gasσic cancer patients(Pancreatic cancer/Chronic Pancreatitis) and nonnal control samples were used. Enzyme immunoassay kits were used for detennination of CEA, CA 199 and MG7 Ag (Biocheck U.S.A), CA 242 and CA 72-4 (Centocor Co. U.S.A), respectively. The data of all 5 markers were increased in patient group compared with normal control group (p⟨0.05). Especially, a definite difference of CA 19-9 was shown between two groups. When 5 markers were used simultaneously, sensitivity of gastric cancer and Pancreatic cancer were increased up to 75.0%(88.0%). This result suggest that CA 242 can be used for screening of Pancreatic cancer. The concentrations of MG 7 Ag in gastic cancer were higher than those of normal control group. However MG 7 Ag alone seemed to be not sufficient enough for screening test but could be available for combination assay with other tumor markers, such as CA 72-4, CA 19-9 and CEA.